Phase 1 × Recruiting × Leukemia, Myelogenous, Chronic, BCR-ABL Positive × Clear all
NCT06904066 2026-04-17

Autologous T Cells Transduced With Retroviral Vectors Expressing TCRs for Participant-specific Neoantigens in Patients With Hematologic Malignancies

National Institutes of Health Clinical Center (CC)

Phase 1 Recruiting
86 enrolled
NCT07166419 2026-04-15

Anti-CD19/20/22 Chimeric Antigen Receptor T Cells (TriCAR19.20.22 T Cells) for the Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma, Acute Lymphoblastic Leukemia, and Chronic Lymphocytic Leukemia

Ohio State University Comprehensive Cancer Center

Phase 1 Recruiting
24 enrolled
NCT03326921 2025-11-14

HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant

Fred Hutchinson Cancer Center

Phase 1 Recruiting
24 enrolled